Crossject SA

Crossject SA is a France-based company that designs and develops medical injection systems. The Company specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The Company's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject's first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The Company has industrial partnerships with Hirtenberger and Recipharm.
  • TickerA1XEH4
  • ISINFR0011716265
  • ExchangeEuronext Paris
  • SectorHealth Care Equipment & Services
  • CountryFrance

Analysts

Adjustment in the number of shares (Crossject)

Adjustment in the number of shares EPS CHANGE CHANGE IN EPS2018 : € -0.73 vs -0.76 ns 2019 : € -0.50 vs -0.53 ns The new number of shares has been adjusted to take into account the exercise of options since September, while the last capital increase (December) was already in our numbers. Therefore, the loss per share seems lower, which is only due to this impact, all other numbers being unchanged. CHANGE IN NAV€ 11.9 vs 12.7 -6.81% The lower NAV per share stems from the higher number of shares after the exercise of options since September (and not from the capital increase which was already...

Success of the capital increase

Success of the capital increase LATEST FACT Crossject has announced that the c.€4m capital increase had been subscribed with, among others, c. 1,656k shares by Gemmes Venture (the group’s historic shareholder, which now controls 30.6% of the share capital) out of a total of c.3.4m new shares. The new number of shares stands at 13.6m and new shares will be listed as from 28 December. IMPACT The capital increase was already included in our numbers. We will only adjust them to account for the conversion of warrants since September that led to a high number of shares pre capital increase.

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - Crossject : Une opération pour financer la transformation - ACHAT, OC 2,1€ vs 2,8€

La société a lancé une AK garantie de 4m€, se clôturant le 14/12, afin de participer au financement du développement et de la structuration de l'outil industriel ainsi que des étapes réglementaires en vue de l'obtention des autorisations d'AMM. Le groupe évalue également son besoin de financement à horizon 12 mois à 11m€. Des financements non dilutifs devraient permettre de combler ses besoins. Cette opération dilutive (-25%) et certains ajustements sur la consommation de trésorerie nous conduisent à réviser notre OC à 2,1€. A l'aube d'une période 2019/20 qui pourrait transformer la société d'...

A €3.9m capital increase before year-end (Crossject)

A €3.9m capital increase before year-end TARGET CHANGE CHANGE IN TARGET PRICE€ 11.1 vs 14.9 -25.6% Our target price is revised downward on the capital increase to come (December), which will lead to the issuance of c. 3.4m new shares. CHANGE IN EPS2018 : € -0.76 vs -0.91 ns 2019 : € -0.53 vs -0.73 ns Our forecasts have not changed. The higher number of shares simply implies that short-term losses are divided by a bigger number, thus the (wrong) impression on an EPS basis that forecast losses have shrunk. CHANGE IN NAV€ 12.7 vs 17.2 -26.1% Our NAV valuation is adjusted one the one hand by a...

A €3.9m capital increase

A €3.9m capital increase FINANCING ISSUE FACT Crossject announced it would issue new shares, a maximum of 3.4m with subscription rights, to be listed before year-end (28 December), with total potential proceeds of c.€3.9m. ANALYSIS In short, the subscription period will be 3-14 December. Three subscription rights will give the right to subscribe to one new share at €1.16, thus a theoretical price for subscription rights of €0.14 based on yesterday’s closing price. Gemmes Venture, the historic and main shareholder of Crossject, has committed itself to subscribing a number of shares of at...

Adjustment in the number of shares (Crossject)

Adjustment in the number of shares EPS CHANGE CHANGE IN EPS2018 : € -0.73 vs -0.76 ns 2019 : € -0.50 vs -0.53 ns The new number of shares has been adjusted to take into account the exercise of options since September, while the last capital increase (December) was already in our numbers. Therefore, the loss per share seems lower, which is only due to this impact, all other numbers being unchanged. CHANGE IN NAV€ 11.9 vs 12.7 -6.81% The lower NAV per share stems from the higher number of shares after the exercise of options since September (and not from the capital increase which was already...

Success of the capital increase

Success of the capital increase LATEST FACT Crossject has announced that the c.€4m capital increase had been subscribed with, among others, c. 1,656k shares by Gemmes Venture (the group’s historic shareholder, which now controls 30.6% of the share capital) out of a total of c.3.4m new shares. The new number of shares stands at 13.6m and new shares will be listed as from 28 December. IMPACT The capital increase was already included in our numbers. We will only adjust them to account for the conversion of warrants since September that led to a high number of shares pre capital increase.

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - Crossject : Une opération pour financer la transformation - ACHAT, OC 2,1€ vs 2,8€

La société a lancé une AK garantie de 4m€, se clôturant le 14/12, afin de participer au financement du développement et de la structuration de l'outil industriel ainsi que des étapes réglementaires en vue de l'obtention des autorisations d'AMM. Le groupe évalue également son besoin de financement à horizon 12 mois à 11m€. Des financements non dilutifs devraient permettre de combler ses besoins. Cette opération dilutive (-25%) et certains ajustements sur la consommation de trésorerie nous conduisent à réviser notre OC à 2,1€. A l'aube d'une période 2019/20 qui pourrait transformer la société d'...

A €3.9m capital increase before year-end (Crossject)

A €3.9m capital increase before year-end TARGET CHANGE CHANGE IN TARGET PRICE€ 11.1 vs 14.9 -25.6% Our target price is revised downward on the capital increase to come (December), which will lead to the issuance of c. 3.4m new shares. CHANGE IN EPS2018 : € -0.76 vs -0.91 ns 2019 : € -0.53 vs -0.73 ns Our forecasts have not changed. The higher number of shares simply implies that short-term losses are divided by a bigger number, thus the (wrong) impression on an EPS basis that forecast losses have shrunk. CHANGE IN NAV€ 12.7 vs 17.2 -26.1% Our NAV valuation is adjusted one the one hand by a...

A €3.9m capital increase

A €3.9m capital increase FINANCING ISSUE FACT Crossject announced it would issue new shares, a maximum of 3.4m with subscription rights, to be listed before year-end (28 December), with total potential proceeds of c.€3.9m. ANALYSIS In short, the subscription period will be 3-14 December. Three subscription rights will give the right to subscribe to one new share at €1.16, thus a theoretical price for subscription rights of €0.14 based on yesterday’s closing price. Gemmes Venture, the historic and main shareholder of Crossject, has committed itself to subscribing a number of shares of at...

A director bought 10,000 shares at 6.030EUR and

A director at Crossject bought 10,000 shares at 6.030EUR and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boa...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Anaïs Dudout

Proxy Report - 17/05/2018

Nous regrettons le choix de la société de mettre en place les droits de vote double sous conditions de détention au nominatif depuis au moins de xu ans, qui constituent une rupture du principe de démocratie actionnariale et qui impose des coûts de passage au nominatif réellement importants pour de nombreux gérants d'actifs. Nous recommandons l'opposition à la résolition 11. Notons que la société a publié dans les délais légaux son rapport des commissaires aux comptes sur les comptes sociaux, ce qui est positif. Nous pourrons ainsi recommander l'approbation à la première résolution.

Jehanne Leroy

Etude de l'AG du 17/05/2017

Amélioration significative par rapport à l'an dernier : le rapport de gestion a, cette année, été publié dans les délais légaux spécifiques au marché Alternext (15 jours avant l'AG). Cependant, la société ne communique toujours pas dans les délais légaux les rapports des commissaires aux comptes sur les comptes ou sur les convention réglementées.​

ResearchPool Subscriptions

Get the most out of your insights

Get in touch